The rankings are built upon the YouGov BrandIndex Positive Satisfaction Score, from the comprehensive brand health tracking tool that gathers daily data from over 350 brands in Vietnam. This is the result of more than 18,000 consumer surveys for the Finance sector conducted annually through this tool.

The Bank Satisfaction Rankings 2025 for Vietnam reveal a dynamic shift in customer satisfaction within the Vietnamese banking sector, with several institutions demonstrating significant changes in their standings. This indicates evolving consumer expectations and a heightened level of competition.

The Bank Satisfaction Rankings 2025 for Vietnam serve as a useful source of information for customers seeking banks that offer excellent customer experience. Banks should prioritise customer satisfaction and build long-term relationships with them to improve their ranking and become more prominent in the market. Only in this way can banks harness the power of satisfaction to build a loyal customer base, enhance brand awareness, and drive business growth.

Shifts in the rankings, with SHB recording the largest growth in customer satisfaction, Techcombank tops the ranking

The post Do Anh Tu Resigns from the Boards of TPBank and Tien Phong Securities appeared first on Vietnam Insider.

Vietnamese cybersecurity firm Verichains played a crucial role in investigating the $1.5 billion cryptocurrency hack that hit Bybit, marking one of the largest cyberattacks in crypto history.

Verichains’ Swift Response to the Attack

On February 21, hackers exploited Bybit’s cold wallet, stealing 400,000 ETH. Upon learning of the breach, Thanh Nguyen, founder of Verichains, immediately mobilized his team. Within hours, they coordinated with Bybit and flew to Dubai to analyze the incident.

Just three days later, Verichains released a detailed 28-page report, the first comprehensive analysis of the breach. Their findings confirmed that the attack originated from Safe, a third-party multisignature wallet service used by Bybit. Hackers—later linked to Lazarus Group—manipulated JavaScript code to create a fraudulent transaction, tricking Bybit’s signers into unknowingly approving the transfer.

Bybit CEO Ben Zhou praised the Verichains team, stating: “They are probably the most knowledgeable cybersecurity experts in the world. I was truly surprised and impressed when I learned they were from Vietnam.”

Who Is Verichains?

Founded in 2017, Verichains has emerged as one of the world’s leading blockchain security firms, providing security solutions for over 200 global clients, including Binance, Galaxy Digital, Polygon, BNB, Aptos, and Kakao. The company has previously assisted in handling some of the biggest crypto hacks, such as: The $600 million Binance Smart Chain bridge attack; The $650 million Ronin bridge hack affecting Sky Mavis in 2022

In March 2023, Verichains launched Revela, a tool designed to enhance blockchain transparency and security, earning high praise from industry leaders like Aptos co-founder Mo Shaikh.

Bybit’s Security Overhaul

Following the breach, Bybit has committed to major security upgrades, with CEO Ben Zhou personally overseeing cybersecurity measures.
The company is adopting “bank-level” security protocols to enhance asset protection. Weekly security reports will be reviewed at the highest level.
Bybit plans to strengthen its partnership with Verichains for ongoing security improvements.

Despite the hack, Bybit’s trading volume surged past $48 billion by February 26, with liquidity levels exceeding pre-attack figures.
“This incident is a wake-up call for the entire crypto industry. We see it as an opportunity to strengthen security and build a more resilient ecosystem,” a Bybit representative stated.

Related

37th Annual Roth Conference

• Location: The Laguna Cliffs Marriot Resort & Spa – Dana Point, CA
• Date: Tuesday, March 18, 2025
• Format: One-on-one meetings with institutional investors

iAccess Alpha Virtual Best Ideas Spring Investment Conference 

• Location: Virtual
• Date: Tuesday, March 25, 2025 and Wednesday, March 26, 2025
• Format:
• To register and schedule a one-on-one meeting with DoubleDown, please visit the conference website https://www.iaccessalpha.com/home.

If you have questions about DoubleDown or are interested in conducting a conference call or meeting with management, please contact the company’s investor relations firm, JCIR, at (212) 835-8500 or via email at ddi@jcir.com.

About DoubleDown Interactive
DoubleDown Interactive Co., Ltd. is a leading developer and publisher of digital games on mobile and web-based platforms. We are the creators of multi-format interactive entertainment experiences for casual players, bringing authentic Vegas entertainment to players around the world through an online social casino experience. The Company’s flagship social casino title, DoubleDown Casino, has been a fan-favorite game on leading social and mobile platforms for years, entertaining millions of players worldwide with a lineup of classic and modern games. The Company’s subsidiary, SuprNation, also operates three real-money iGaming sites in Western Europe.

Company Contact:
Joe Sigrist
ir@doubledown.com
+1 (206) 773-2266
Chief Financial Officer
https://www.doubledowninteractive.com

Investor Relations Contact:
Joseph Jaffoni or Richard Land
JCIR
+1 (212) 835-8500
DDI@jcir.com

Source: Crypto Insider

Robotics: Optimizing and personalizing surgery

With CORIOGRAPH^◊ Pre-Op Planning and Modeling Services advanced technology and the CORI Surgical System’s image-agnostic solution for robotic-assisted knee and computer-guided hip replacement procedures, Smith+Nephew offers a highly personalized approach for both surgeons and their patients. CORIOGRAPH’s recent addition of support for hip procedures expands the platform’s reach to provide advanced planning and simulation technology for THA. A defining feature of the technology is the ability to simulate a patient’s functional activities of daily living (ADLs) specific to their anatomy.¹

Alongside these advancements, the CORI^◊ Digital Tensioner enhances the level of personalization in knee procedures by providing objective gap data for planning and execution of the procedure.^2-4 Now available for UKA, TKA, and Revision TKA, the CORI Digital Tensioner is designed to deliver accurate gap balance measurements with the CORI Surgical System for optimizing the surgical plan to align with each patient’s unique soft tissue anatomy.

These cutting-edge technologies enable a highly personalized and tailored surgical approach with the CORI Surgical System, ensuring that patient-specific needs are met. Learn more by visiting the CORIOGRAPH  webpage here.

Hips: Best-in-class just got better

Smith+Nephew’s new CATALYSTEM^◊ Primary Hip System is designed to address the evolving demands of primary hip surgery – including the increased adoption of anterior approach procedures. It features a triple-taper stem design with uniform proximal loading,⁵ and the reduced distal stem geometry and shorter lengths are ideal for anterior approach – and suitable for all approaches.⁶

Smith+Nephew’s total hip arthroplasty (THA) portfolio was recently recognized in the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry. It highlighted the exceptional performance of proprietary OXINIUM^◊ (Oxidized Zirconium) on highly cross-linked polyethylene where the data indicated the combination has the highest survivorship rate (>94.1%) among all bearing combinations over a 20-year period for THA.⁷ Read the press release here.

Knees: Raising the bar in revisions

Smith+Nephew recently launched proprietary OXINIUM implant technology on the LEGION^◊ Hinged Knee (HK) System that delivers the durability of metals, the wear resistance of ceramics, and corrosion resistance better than both metal and ceramic.^8-14 Part of the LEGION Total Knee (TK) System, the LEGION HK System is designed to provide a natural range of motion with medial pivot, lateral roll back, and screw home. Since 2011, the LEGION HK System has enabled surgeons to transition intraoperatively from a constrained revision knee implant to a CoCr-hinged assembly. Learn more by visiting the LEGION HK webpage here.

AETOS^◊ Shoulder System: Elegant design. Elevated experience.

Smith+Nephew recently received 510(k) clearance from the FDA for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless). AETOS Stemless addresses the growing demand for anatomic total shoulder replacement with a small operating room footprint allowing for an efficient procedure.¹⁵ It is designed to maximize metaphyseal fixation and stability with an inlay collar, cruciate fins, and porous titanium coating to encourage biological fixation.^16,17 Learn more by visiting the AETOS webpage here.

To learn more about Smith+Nephew’s advanced solutions for Orthopaedic Reconstruction, please visit our booth (#3729) at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in San Diego March 11-13, 2025 or visit wwww.smith-nephew.com.

 – ends –

Media Enquiries

Dave Snyder          +1 (978) 749-1440 

Smith+Nephew      david.snyder@smith-nephew.com

References

1. Smith+Nephew 2020. Internal Report. EA/RECON/VISIONAIRE/001/v6.
2. Smith+Nephew 2022. Optimus TKA Tensioner Gap Assessment Verification Report. Internal Report. 10059269.
3. Smith+Nephew 2022. Tensioner KPC: Tensioner Calibration Check. Internal Report. TR100116, REV B.
4. Smith+Nephew 2022. CORI TENSIONER. 2020.04 Study Cases. Preliminary Analysis Report REV B.
5. Smith + Nephew 2024. Finite Element Analysis of the CATALYSTEM Hip Stem Design. Internal Report. OR-24-025
6. Smith + Nephew 2024. Surgeon Feedback on the CATALYSTEM Total Hip System. Internal Report.  CSD.REC.24.001
7. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) Hip, Knee & Shoulder Arthroplasty: 2024 Annual Report Adelaide; AOA, 2024:1–629. Available at: https://aoanjrr.sahmri.com/annual-reports-2024. Accessed December 11, 2024.
8. Sheth NP, Lementowski P, Hunter G, Garino JP. Clinical applications of oxidized zirconium. J Surg Orthop Adv. 2008;17(1):17-26.
9. Davidson JA, Mishra AK, Poggie RA. Friction and UHMWPE wear of cobalt alloy, zirconia, titanium nitride, and amorphous diamond-like carbon implant bearing surfaces. Poster presented at: 4th World Biomaterials Con1992; Berlin, FRG.
10. Hobbs L, Rozen V, Mangin S, Treska M. Oxidation Microstructures and Interfaces in the Oxidized Zirconium Knee. Int J Appl Ceram Technol. 2005.
11. Long M, Riester L, Hunter G. Nano-Hardness Measurements of Oxidized Zr.2.5Nb and Various Orthopaedic Materials. 1998.
12. Smith+Nephew 2010. Hip Simulator Wear Testing of XLPE Liners Against Oxidized Zr-2.5Nb and BIOLOX Delta Heads. Interal Report. OR-10-155
13. Smith+Nephew 2010. OR-10-155.
14. Smith+Nephew 2016. OR-16-127
15. Smith+Nephew 2023. AETOS Instruments & Trays.
16. Internal Report. ER-04-0990-0020 REV B
17. Pilliar RM. Cementless implant fixation—toward improved reliability. Orthopedic Clinics of North America. 2005;36(1):113-119

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.

^◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

.

Source: Crypto Insider

If you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, March 09, 2025 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

On February 27, 2025, Viatris issued a press release reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics. In addition, Viatris provided lower-than-expected full-year guidance for 2025. Viatris also provided an update on remediation work at a manufacturing facility in India following receipt of a warning letter and import alert from the U.S. Food and Drug Administration, advising that it was “more than halfway through its remediation efforts and expects to be completed in a few months at which time the Company anticipates requesting FDA to conduct a reinspection of the facility.” 

On this news, Viatris’s stock price fell $1.71 per share, or 15.21%, to close at $9.53 per share on February 27, 2025.

To learn more about the Viatris Inc. investigation, go to www.faruqilaw.com/VTRS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d1f7d2e5-d2f5-42a9-81e9-41d961ebc07d

Source: Crypto Insider

If you suffered losses exceeding $75,000 in Pacira between August 2, 2023 and August 8, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, March 09, 2025 (GLOBE NEWSWIRE) —  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pacira BioSciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) and reminds investors of the March 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

According to the Complaint, on August 9, 2024, Pacira announced that the New Jersey District Court invalidated its ‘495 patent, holding that eVenus did not infringe on the ‘495 patent on the basis on obviousness and anticipation. The Complaint alleges that this ruling came shortly after Pacira’s submission of additional evidence to the Court, which the Court stated would not have any impact on the basis for the decision. The Complaint further alleges that this ruling was secondary to the same court’s ruling impacting claims construction for both Pacira’s ‘495 and ‘336 patents in eVenus’s favor.

According to the Complaint, Pacira’s announcement that its ‘495 patent was invalidated surprised investors and analysts alike as they reacted immediately to the revelations. The Complaint alleges that the price of Pacira’s common stock declined dramatically. According to the Complaint, from a closing market price of $22.36 per share on August 8, 2024, Pacira’s stock price fell to a low of $11.70 per share on August 9, 2024, a decline of over 47% in a single day, thereby damaging investors.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Pacira’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Pacira BioSciences, Inc. class action, go to www.faruqilaw.com/PCRX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fde2fe7b-165f-4f25-b274-82a516dcf056

Source: Crypto Insider

If you suffered substantial losses and wish to serve as lead plaintiff of the Skyworks class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-skyworks-solutions-inc-class-action-lawsuit-swks.html

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.

CASE ALLEGATIONS: Skyworks designs, develops, manufactures, and markets proprietary semiconductor products.

The Skyworks class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Skyworks’ projected revenue outlook and anticipated growth while also minimizing risk from smartphone upgrade cycles and macroeconomic fluctuations; (ii) Skyworks’ optimistic reports of growth, earnings potential, and anticipated margins fell short of reality as they relied far too heavily on Skyworks’ partnership with its largest customer and launch of that customer’s newest phone; and (iii) Skyworks was not equipped to execute on their perceived growth potential.

The Skyworks class action lawsuit further alleges that on February 5, 2025, Skyworks announced its financial results for the first quarter of fiscal year 2025 and provided lower-than anticipated revenue guidance for the second quarter of fiscal year 2025, attributing the results and low guidance to a “competitive landscape” that had “intensified” in recent years. On this news, the price of Skyworks stock fell more than 24%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Skyworks securities during the Class Period to seek appointment as lead plaintiff in the Skyworks class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Skyworks class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Skyworks class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Skyworks class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez, Jennifer N. Caringal
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        info@rgrdlaw.com

Source: Crypto Insider

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) between April 2, 2020 and January 16, 2025, both dates inclusive (the “Class Period”), of the important March 31, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Walgreens common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Walgreens class action, go to https://rosenlegal.com/submit-form/?case_id=27235 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 31, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants, throughout the Class Period, failed to disclose to investors that: (1) contrary to Walgreens’ purported commitment to improved regulatory compliance, Walgreens continued to engage in widespread violations of federal law governing the dispensation of prescription medication and reimbursement of the same; (2) the foregoing conduct, when revealed, would subject Walgreens to a heightened risk of further regulatory scrutiny, civil liability, and reputational harm; (3) Walgreens’ revenues from the sale of prescription medications were unsustainable to the extent that they derived from unlawful conduct; and (4) as a result, Walgreens’ public statements were materially false and misleading at all relevant times.   When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Walgreens class action, go to https://rosenlegal.com/submit-form/?case_id=27235 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        case@rosenlegal.com
        www.rosenlegal.com

Source: Crypto Insider